BERN. Three years after Switzerland established its national long Covid registry, the first comprehensive analysis paints a picture that is neither as bleak as feared nor as benign as hoped. Of the roughly 12,000 patients enrolled across fourteen cantons, about half report substantial recovery within two years, while one in five remains unable to work full time.
The registry, run by a university consortium with support from the Federal Office of Public Health, is the largest dataset of its kind in the country. It tracks symptoms, treatment pathways, work capacity and quality of life at six month intervals, offering the first solid numbers in a debate that has run largely on anecdote. Participation is voluntary and open to anyone with a confirmed diagnosis lasting beyond twelve weeks.
The findings complicate several early assumptions. Recovery is most likely in the first eighteen months and rare after the third year, which argues for intensive early rehabilitation rather than watchful waiting. Vaccination before infection roughly halves the risk of prolonged illness, and reinfection resets the clock in a minority of patients. Women are affected roughly twice as often as men, a pattern the data confirm but cannot yet explain.
The economic footprint is now measurable. The registry team estimates direct medical costs of CHF 9,000 per patient per year for those with persistent symptoms, before counting disability pensions and lost productivity. Disability insurance has opened several thousand long Covid files, with average case durations well above those for comparable conditions. Productivity losses are estimated at several hundred million francs a year.
Doctors treating these patients describe a system learning on the job. Dedicated post-viral clinics now operate in all five university hospitals, but capacity covers perhaps a third of demand, and general practitioners report uncertainty about which interventions actually help beyond pacing, symptom management and gradual rehabilitation. Waiting lists for the specialist clinics run to several months in the French speaking cantons.
A spokesperson for the insurers' association said the data justified the specialised clinics but urged discipline about unproven therapies. “Desperation is a market, and we should be careful what we fund,” the spokesperson said.
Patient organisations welcome the numbers while faulting the pace. They note that recognition of long Covid for disability purposes still varies between cantonal offices, and that many patients exhaust their savings during the assessment period. Their central demand, a binding national care pathway with defined waiting time guarantees, remains unmet. An estimated 40,000 people live with persistent symptoms nationwide.
Sceptics within the medical community raise a methodological caution. Registry participants are self selected and disproportionately severe cases, they argue, so the findings describe the sickest slice rather than the true population burden. The consortium acknowledges the limitation and has begun a population based sample to correct it. Similar debates surrounded chronic fatigue syndrome for decades.
The political response is taking shape slowly. The health ministry has extended registry funding through 2029, and a parliamentary motion calling for a national post-infectious disease strategy, covering conditions beyond Covid, passed the lower house this spring. Cantonal health directors are discussing whether post-viral clinics should become a permanent, jointly financed service. A separate motion seeks mandatory reporting of post-viral illness by cantonal laboratories.
For households, the findings carry a practical message. Persistent symptoms after infection warrant early assessment rather than endurance, and vaccination remains the cheapest insurance against the worst outcomes. Employers, meanwhile, face growing legal clarity that long Covid can constitute a disability requiring accommodation. Employers' associations have begun publishing guidance on phased returns to work.
The registry's next report, due in 2028, will answer the question that matters most: whether those still ill at three years recover at all. Until then, Switzerland has at least replaced argument with evidence.
The registry has also changed how the condition is discussed. Three years ago long Covid was contested territory, dismissed by some as exhaustion and exaggerated by others into catastrophe. The data now support a narrower, more useful claim: a real condition, uncommon but not rare, that medicine can often improve and occasionally cannot.